New Frontiers Science Park

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Retrieved on: 
Thursday, August 25, 2022
MSD, AstraZeneca, BRCA2, Olaparib, Precision medicine, U.S. Securities and Exchange Commission, Myriad Genetics, GLOBE, Classification, Olympia, Tf–idf, Risk, Patient, BRCA1, Genetics, Death, Genetic testing, SALT, DNA, Cancer, Biomarker, Partnership, MHLW, NASDAQ, Breast International Group, Association for Molecular Pathology v. Myriad Genetics, Inc., New Frontiers Science Park, Ministry of Health, Labour and Welfare, Prequel, Myriad, Private Securities Litigation Reform Act, BRCA, Breast cancer, HIV disease progression rates, MYGN, Nominal interest rate, Sumathi Best Television Current Reporting Award, Fast Company, HER2, Medical imaging, Pharmaceutical industry, Health

This most recent coverage expansion confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.

Key Points: 
  • This most recent coverage expansion confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.
  • BRACAnalysis Diagnostic System is designed to detect and interpret germline BRCA1 and BRCA2 variants.
  • The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2-negative high-risk early breast cancer.
  • BRACAnalysis is a diagnostic system that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.

Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer

Retrieved on: 
Saturday, March 12, 2022
MSD, Association for Molecular Pathology v. Myriad Genetics, Inc., Risk, Partnership, Guideline, Cyprus Securities and Exchange Commission, Regulation of tobacco by the U.S. Food and Drug Administration, AstraZeneca, Health, Precision medicine, Private Securities Litigation Reform Act, Olympia, Classification, HIV disease progression rates, Breast cancer, HER2, Biomarker, Fast Company, FDA, Olaparib, Sumathi Best Television Current Reporting Award, National Cancer Institute, DNA, Merck, Ovarian cancer, GLOBE, Patient, Neoplasm, BRCA1, NASDAQ, Myriad Genetics, SALT, PARP, BRCA2, Breast International Group, New Frontiers Science Park, MYGN, Security (finance), Genetics, Genomics, Merck & Co., Genetic testing, Technology, State, BRCA, COVID-19, Food, Diagnosis, Pharmaceutical industry, Medical imaging, Myriad

This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.

Key Points: 
  • This most recent regulatory approval confirms the benefits of using biomarkers to help guide care for patients with breast cancer, said Nicole Lambert, chief operating officer, Myriad Genetics.
  • BRACAnalysis CDx is intended to detect and interpret germline BRCA1 and BRCA2 variants.
  • The test identifies deleterious or suspected deleterious germline BRCA variants in patients with HER2 negative high-risk early breast cancer.
  • BRACAnalysis is a companion diagnostic test that classifies a patients clinically significant variants (DNA sequence variations) in the germline BRCA1 and BRCA2 genes.